ArticleMedicine2026
Global, regional, and national burden of clavicle, scapula, or humerus fracture in 204 countries and territories, 1990 to 2021: A systematic analysis from the Global Burden of Disease Study 2021.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Clavicle, scapula, or humerus fracture represent a major public health challenge, yet their epidemiology and health burden remain poorly characterized. Using the Global Burden of Disease 2021 framework, we quantified incidence, prevalence, and years lived with disability (YLDs) of clavicle, scapula, or humerus fractures across 204 countries from 1990 to 2021. Estimates were stratified by age, sex, region, and socio-demographic index (SDI), and reported with 95% uncertainty intervals (UIs) from Bayesian models. Globally, the age-standardized incidence rate (ASIR) declined from 276.68 (95% UI: 219.06-346.71) per 100,000 person-years in 1990 to 220.94 (95% UI: 172.60-280.99) per 100,000 person-years in 2021, with an estimated annual percentage change of -0.78% (95% UI: -0.82% to -0.73%). High SDI regions showed the greatest ASIR (300.30 per 100,000 person-years), age-standardized prevalence rate (112.03 per 100,000 person-years), and age-standardized YLDs rate (3.72 per 100,000 person-years). In 2021, Eastern Europe had the highest ASIR (465.06 per 100,000 person-years), while Australasia led in age-standardized prevalence rate (151.42 per 100,000 person-years) and age-standardized YLDs rate (5.04 per 100,000 person-years). China ranked first in absolute prevalence (1.21 million, 95% UI: 1.04-1.39 million) and YLDs (40,235, 95% UI: 24,471-61,196). Despite declines in age-standardized rates, absolute cases increased substantially, highlighting demographic and regional disparities. Priority populations for targeted prevention include women aged ≥60 years and residents of high-SDI regions, as these strata accounted for the highest burden across incidence/prevalence/YLD rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.